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Memory dementia perineuronal net
Object recognition TESTAlzheimer's disease is the most prevalent tauopathy and cause of dementia. We investigate the hypothesis that
reactivation of plasticity can restore function in the presence of neuronal damage resulting from tauopathy. We
investigated two models with tau hyperphosphorylation, aggregation and neurodegeneration: a transgenic
mouse model in which the mutant P301S tau is expressed in neurons (Tg P301S), and a model in which an
adeno-associated virus expressing P301S tau (AAV-P301S) was injected in the perirhinal cortex, a region critical
for object recognition (OR) memory. Both models show profound loss of ORmemory despite only 15% neuronal
loss in the TgP301S and26% inAAV-P301S-injectedmice. Recordings fromperirhinal cortex slices of 3month-old
P301S transgenic mice showed a diminution in synaptic transmission following temporal stimulation.
Chondroitinase ABC (ChABC) can reactivate plasticity and affect memory through actions on perineuronal nets.
ChABCwas injected into the perirhinal cortex and animals were tested for ORmemory 1week later, demonstrat-
ing restoration of ORmemory to normal levels. Synaptic transmission indicated by fEPSP amplitudewas restored
to control levels following ChABC treatment. ChABC did not affect the progression of neurodegenerative
tauopathy. These ﬁndings suggest that increasing plasticity by manipulation of perineuronal nets offers a novel
therapeutic approach to the treatment of memory loss in neurodegenerative disorders.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Perineuronal nets (PNNs) are extracellular matrix structures found
predominantly around inhibitory parvalbumin-positive interneurons
in the cortex and other brain regions. They play a part in the termination
of developmental critical periods, and their degradation restores
plasticity and enhances recovery from various types of CNS damage
(Frischknecht and Gundelﬁnger, 2012; Kwok et al., 2011; Wlodarczyk
et al., 2011). While PNN digestion with chondroitinase ABC (ChABC)
has enabled restoration of function after focal lesions such as stroke
and spinal cord injury (Bradbury et al., 2002; Soleman et al., 2012), it
is not establishedwhether re-activation of plasticity by ChABCmight re-
store CNS function following the diffuse neuronal loss and damage that
accompanies neurodegenerative disease caused by tau pathology. Loss
of memory is a feature of many neurodegenerative diseases, and PNNs
have been implicated in memory mechanisms (Gogolla et al., 2009;. This is an open access article underRomberg et al., 2013). We recently showed that digestion of PNNs in
the perirhinal cortex (PRh), a structure critical for object recognition
(OR) memory (Bartko et al., 2007; Mumby and Pinel, 1994; Winters
et al., 2004), greatly prolonged long-term OR memory in wild type
(WT) mice, and an identical memory prolongation was seen in mice
lacking CNS Crtl1/Hapln1, an essential component of PNNs (Romberg
et al., 2013). As the PRh is affected and recognition memory is impaired
in human tauopathies such as Alzheimer's and Pick's diseases (Braak
and Braak, 1991, 1992; Gold and Budson, 2008; Hornberger and
Piguet, 2012), these results suggest that manipulation of PNNs could
be a possible method for restoration of memory and compensation for
neuronal dysfunction and loss in such diseases. In the present study,
we tested whether PNN digestion can restore memory in the presence
of the diffuse lesion produced by tau pathology. We used two lesion
models: 1. transgenicmice expressing human tauwith the P301Smuta-
tion, responsible for cases of frontotemporal dementia and parkinson-
ism linked to chromosome 17 (FTDP-17) (Spillantini and Goedert,
2013). These transgenic mice show progressive tau pathology in both
central and peripheral nervous systems (Allen et al., 2002; Delobelthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the human P301S tau was injected into the PRh of adult C57BL/6S
mice. The localized tauopathy in this model avoids motor confounds,
which occur with damage to motoneuons in transgenic P301S tau
mice after six months.
Both Tg P301S mice and AAV P301S-injected mice developed a pro-
gressive tauopathy and a severe deﬁcit in OR memory together with a
deﬁcit in synaptic transmission. Digestion of PNNs in the PRh with
chondroitinase ABC (ChABC) – which targets the chondroitin sulphate
proteoglycans (CSPGs), a major component of PNNs, critically responsi-
ble for their effect on plasticity (Carulli et al., 2010; Dityatev et al., 2010;
Frischknecht et al., 2009; Kwok et al., 2012) – fully restored ORmemory
and synaptic transmission. These ﬁndings indicate that modiﬁcation of
PNNs can enable transient functional recovery from CNS dysfunction
caused by diffuse neurodegeneration.
Materials and methods
Mice
Homozygous transgenic male mice expressing human mutant
P301S tau (Tg P301S) under the control of the murine Thy1 promoter
were used for this study. In humans, the presence of the P301Smutation
in the Tau gene leads to a progressive tauopathy causing frontotemporal
dementia (Bugiani et al., 1999). This mousemodel presents progressive
tau pathologywith the ﬁrst tau deposits in homozygousmice appearing
at 2months of age and developinguntil the age of 5–6monthswhen the
mice have to be culled due to their motor phenotype (Allen et al., 2002;
Delobel et al., 2008). Age- and sex-matched C57BL/6Smice (Harlan, UK)
were used as controls. Behavioral studies were performed in male mice
at 1, 2 and 3 months of age, before the development of the overt motor
phenotype (number of animals: 1 month: WT n = 7, P301S n = 9; 2
months: WT n = 5, P301S n = 7; 3 months: WT, n = 6 P301S n =
10). In order to ensure the speciﬁcity of the transgene effect in the be-
havioral deﬁcit, heterozygous male Tg P301S mice (P301S Het) which
start to develop tau pathology at the age of 7 months and have to be
culled at the age of 14–15 months, were tested with their littermate
controls at 3 and 7 months of age (number of animals: 3 months: WT
n = 6, P301S Het n = 7; 7 months: WT n = 8, P301S Het n = 7). For
AAV injection 8–9 week old male C57BL/6S mice (Harlan, UK) were
used. Animals had unrestricted access to food and water, and were
maintained on a 12 h light/dark cycle (lights off at 7:00 P.M.). All behav-
ioral testing was conducted during the light phase of the cycle. All ex-
periments were carried out in accordance with the UK Home Ofﬁce
Regulations for the Care and Use of Laboratory Animals and the UK An-
imals (Scientiﬁc Procedures) Act 1986.
Spontaneous object recognition task
The spontaneous object recognition (OR) taskwas conducted as pre-
viously described for mice (Romberg et al., 2013), using a Y-shaped ap-
paratus adapted formice. The Y-apparatus had high, homogenouswhite
walls constructed from Perspex to prevent the mouse from looking out
into the room, thereby maximizing attention to the stimuli. One arm
was used as the start arm, and the other two arms were used to display
the objects (dimensions approximately 10 cm× 4 cm× 4 cm). All walls
were 30 cm high, and each arm was 15 cm in length and 8 cm wide. A
lamp illuminated the apparatus and a video camera was mounted
50 cmabove the apparatus to record trials for analysis. Allmicewere ha-
bituated in three consecutive daily sessions in which they were placed
in the start arm and left to explore the empty Y-apparatus for 5 min.
The following test sessions were separated by a minimum of 48 h.
Each test session consisted of a sample phase and a choice phase. In
the sample phase, the animal was placed in the start arm and left to ex-
plore the two identical objects, which were placed on the end of two
arms for 5 min. The choice phase followed after a delay of either1 min or 3 h which the animal spent in the home cage. The choice
phase was procedurally identical to the sample phase, except that one
arm contained a novel object, whereas the other arm contained a copy
of the object which was presented in the sample phase. An unused
copy of the repeated object was used in order to avoid olfactory distur-
bance. Each animal received 2 test sessions for each delay. A different
object pair was used for each session for a given animal, and the order
of exposure to object pairs as well as the designated sample and novel
objects for each pair were counterbalanced within and across groups.
This testwas performed 7 days after ChABC injections. The object explo-
ration time was assessed from video recordings of the sample and
choice phase. The direct nasal or head contacts only were regarded as
an exploratory behavior. For the choice phase, a discrimination ratio
was calculated by dividing the difference in exploration of the novel
and familiar objects by the total object exploration time. Therefore,
the discrimination ratio varies from 0 (equal exploration for novel and
familiar objects) to 1 (exploration of the novel object only). The mean
discrimination ratio across two test sessionswas calculated for each an-
imal. Group means were compared by ANOVA followed by Tukey post-
hoc test with a signiﬁcance level of p b 0.05, using GraphPad Prism ver-
sion 5.0. A two-tailed t-test was used for two-group comparisons.
(Number of mice for P301S homozygous study: P-nase n= 16, ChABC
n = 13; Control: P-nase n = 7, ChABC n = 5; number of mice for
P301S heterozygous study: P-nase n = 4, ChABC n = 4; Control: P-
nase n = 4, ChABC n = 3; number of mice for the AAV-fpmax study:
P-nase n = 6, ChABC n = 6; AAV-TauWT: P-nase n = 6, ChABC n =
6; AAV-P301S: P-nase n= 6, ChABC n= 6).
ChABC injections
Protease-free ChABC (Seikagaku, Japan) or penicillinase (P-nase;
Sigma-Aldrich, UK) as a non-relevant control enzyme was dissolved in
0.1% BSA to 50 U/ml of concentration and ﬁltered through a 0.2 micron
ﬁlter. Six injections in the PRh (3 per hemisphere, 0.5 μl with a speed
of 0.2 μl/min)were performed stereotaxically under isoﬂurane anesthe-
sia with a 10 μl Hamilton syringe and a 33 gauge needle at the following
sites (inmm frombregma and the surface of skull): 1. anterior–posterior
(AP):−1.8; lateral (L): ±4.6; ventral (V):−4.4, 2. AP:−2.8; L: ±4.8;
V: −4.3 and 3. AP: −3.8; L: ±4.8; V: −3.8. The needle remained in
place at the injection site for 3 min before being slowly withdrawn
over 2 min.
Generation of adeno-associated virus (AAV: serotype 2/6) vectors
Human 4R0N cDNAs encoding wild-type and mutant P301S tau
were each cloned into a pAAV shuttle vector harboring the AAV sero-
type 2 inverted terminal repeats (ITRs) and an expression cassette com-
posed of the mouse PGK1 promoter, the human β-globin intron, a
multiple cloning site (MCS) and the woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) (modiﬁed from Stratagene's
pAAV-MCS vector using standard cloning procedures). Both tau inserts
were generated by PCR from previously described pHA/Tau vectors
(Goedert et al., 1989) using the following primers: Forward 5′ CGA
GTT CTC TCG AGG CCG CCA CCA TGG CTG AGC CCC GCC 3′ and Reverse
5′ CGA GTA CTA GAT CTT CAC AAA CCC TGC TTG GC 3′. PCR products
were digested by XhoI and BglII and subcloned into the MCS of pAAV
shuttle vector (XhoI/BglII) to generate pAAV-PGK-TauWT-WPRE and
pAAV-PGK-Tau P301S-WPRE vectors.
Production and titration of pseudotyped recombinant AAV2/6 vectors
Recombinant AAV2/6 vectors were produced and puriﬁed as previ-
ously described (Dusonchet et al., 2009). Brieﬂy, AAV particles were
generated by transient co-transfection of 293-AAV cells with pAAV
shuttle vectors (bearing AAV2 ITRs) and a pDP6 helper plasmid (coding
for AAV6 capsids) (Grimm et al., 2003) for 48 h. After collection, cells
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were puriﬁed on iodixanol density gradient followed by heparin afﬁnity
chromatography. Finally, AAV particles were eluted in sterile PBS and
stored at −80 °C until use. Following puriﬁcation each batch was
subjected to SDS-PAGE followed by a Coomassie staining to assess
AAV purity. Infectious titers were determined as described previously
(Dusonchet et al., 2009) and expressed in transducing units (TU)/ml.
For the present study, the following vectors were produced: AAV-
TurboGFP (fpmax): 2.8 × 1010 TU/ml; AAV-TauWT: 1.1 × 1010 TU/ml;
and AAV-P301S: 1.7 × 1010 TU/ml.
Stereotaxic injection of AAV vectors
AAV vectors encoding human wild-type tau (AAV-TauWT) or mu-
tant P301S tau (AAV-P301S) were used to generate a local tauopathy
in themouse PRh. AAV-TurboGFP (fpmax) was used as a control vector.
To inject AAV2/6 vectors in the PRh, stereotaxic surgery was performed
under isoﬂurane anesthesia in 8–9weeks oldmale C57BL/6Smice (Har-
lan, UK). In order to cover a signiﬁcant portion of the PRh, the vector
suspension was bilaterally injected at 4 sites (2 sites per hemisphere,
each site injectedwith 0.5 μl at a rate of 0.2 μl/min) using amicrosyringe
pump controller (Micro4,World Precision Instruments). The stereotaxic
coordinates for the PRh used in this study were 1. AP: −1.8 mm; L:
±4.2 mm; V: −4.0 mm and 2. AP: −3.2 mm; L: ±4.1 mm; V:
−3.8 mm. The needle remained in place at the injection site for 3 min
before slow withdrawn over a period of 2 min. The total dose of vector
injected in each animal was 1 × 107 TU. Animals were subjected to
spontaneous OR task at 1 month and 2 months post-injection of the
vector. Number of mice: AAV-fpmax n= 12, AAV-TauWT n= 13, and
AAV-P301S n= 12.
Immunohistochemistry
Animals were perfused transcardially with 4% paraformaldehyde
(PFA) in 0.1 M PBS, pH 7.4. Brains were quickly dissected out and
post-ﬁxed overnight in 4% PFA at 4 °C, and cryoprotected in 30% sucrose
in 0.1MPBS for at least 24 h at 4 °C. Coronal brain sections (30 μm)were
cut on a Leica SM2400 microtome (Leica Microsystems, Bucks, UK) and
stored at 4 °C in 0.1 M PBS containing 0.1% sodium azide. A monoclonal
antibody NeuN (1:400, Millipore) was used for neuronal cell counting.
AT8 (1:1000, Innogenetics) and PHF1 (1:500, a gift of Dr Peter Davies)
were used to detect hyperphosphorylated forms of tau. The biotinylated
Wisteria ﬂoribunda agglutinin (WFA, 1:400, Sigma-Aldrich) was used to
visualize PNNs. Labeling was performed by ﬁrst rinsing tissue with
0.1M phosphate buffered saline (PBS) followed by quenching of endog-
enous peroxidase activity with 10% methanol, 3% H2O2, and 0.1% Triton
X-100 in PBS (PBS-T) for 20 min at room temperature (RT). Sections
were rinsed three times in PBS-T and were subsequently blocked with
5% normal goat serum (NGS) or normal horse serum (NHS), in PBS-T
for 1 h at RT. Sections were then incubated overnight at 4 °C with the
primary antibody diluted in PBS-T. Following 3 washes in PBS they
were incubated for 2 h at RT with the appropriate biotinylated second-
ary antibody (Vectastain; Vector Laboratories) diluted 1:1000 in PBS-T.
The immunostaining was visualized with an avidin–biotin system
(Vectastain; Vector Laboratories) and 3′,3′diaminobenzidine as the
chromogen (DAB kit; Vector Laboratories). Sectionswere thenmounted
on glass slides, examined using a light microscope and photographed
using a digital camera (Leica DM6000 Microsystems).
Electrophysiology
Animals were anesthetized with isoﬂurane and decapitated. The
brain was rapidly removed and placed in ice-cold cutting solution bub-
bled with 95% O2/5% CO2 containing the following (in mM): 132.8 NaCl,
3.1 KCl, 1 CaCl2, 2 MgCl2, 1 K2HPO4, 4 NaHCO3, 5 D-glucose, 0.01 glycine,
1 ascorbic acid, 0.5 myoinositol, 2 pyruvate, and 10 HEPES, adjusted topH 7.35. A midsagittal section was made and the rostral part of one
hemisphere was cut at 45° to the dorsoventral axis (Cho et al., 2000).
The cerebellum was removed from the brain with a further caudal cut
along the dorsoventral axis. The hemisphere was glued by its rostral
end to a Vibratome stage (VT 1000S; Leica). Slices (350 μm) of PRh
were taken in the region−2.5 mm to−4.0 mm rostral from bregma.
Slices were stored submerged in bubbled, artiﬁcial CSF (20–25 °C,
same composition as cutting solution, except 2 mM CaCl2, 1 mM
MgCl2) for 2 h before the onset of recordings. A single slice was placed
in an interface recording chamber superfused by artiﬁcial CSF (30 °C,
ﬂow rate 2 ml/min). Evoked ﬁeld EPSPs (fEPSP) were recorded from
layers II/III fromdirectly below the rhinal sulcus (area 35). A stimulation
electrode was placed in layer II/III on the temporal side (0.5 mm, area
36) of the recording electrode. Stimuli (0.1ms duration)were delivered
to the stimulation electrode at 0.1 Hz. Input/output curves were pro-
duced with stimulation intensities from 50 to 500 μA in steps of 50 μA.
For monitoring baseline synaptic transmission before LTD induction,
fEPSPswere reduced to 50–60% of themaximum amplitude and record-
ed for at least 30 min or until responses were stable (b20% amplitude
change over 30 min), (Number of mice for the study: WT P-nase n =
11, P301S P-nase n = 11, P301S ChABC n = 11). For LTD induction,
900 stimulus pairs (1 ms each, 20 ms). Subsequently, fEPSPs elicited
by 0.1 Hz stimulation were recorded for further 60 min (number of
mice for the study: WT P-nase n = 7, P301S P-nase n = 7, P301S
ChABC n = 6). Field potentials were ampliﬁed with a CyberAmp 320
(Molecular Devices), recorded and analyzed with custom-made
software written in LabView (National Instruments). For ofﬂine LTD
analysis, fEPSPs were averaged across 1 min and the peak amplitude
of the mean fEPSP was expressed relative to the preconditioning base-
line. Group means were statistically compared using either paired or
unpaired t tests or repeated-measures (RM) ANOVA, followed by tests
of simple main effects, if applicable.
Stereology
For stereological counting of neurons, pathological tau or PNN-
positive cells, brain sections were stained with NeuN, AT8 or WFA,
respectively. Immunolabeling of each antibody was revealed using
3,3′-diaminobenzidine tetrahydrochloride (DAB) and coverslips were
applied using DPX mounting medium. Stereology was performed
using an Olympus microscope with the stereological software
StereoInvestigator (MBF Bioscience). A total number of 5–6 sections
per animal (n= 5–6 mice for each group), taken every 12th brain sec-
tions were used for immunohistochemistry. The whole brain section
was ﬁrst highlighted at 4× objective and PRh contour was outlined.
Sample countingwindowswere identiﬁedusing the computer software.
The number of sample counting windows was normally between 15
and 20. The number of NeuN, AT8 orWFA-positive cells in eachwindow
was counted at 40×magniﬁcation. The counting frame and the counting
grid were set by the operator; 40 μm× 40 μmand 200 μm× 200 μm, re-
spectively. Movements among counting frames of each grid were con-
trolled by a motorized x–y microscope stage. Cells located inside the
counting frame or touching its top or right borders only were counted.
For the Z calibration, the tissue thickness at every counting frame was
determined and the mean of sections thickness was taken into account
for calculating the total number of cells. The total number of NeuN, AT8
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Sarkosyl insoluble tau extraction
P-nase or ChABC was stereotaxically injected into C57BL/6S wild-
type and P301S mice as described in the ChABC injections section.
After 2 weeks from the injection, themicewere culled by cervical dislo-
cation and brains were excised for sarkosyl-insoluble tau preparation,
which was performed as previously described (Allen et al., 2002;
Delobel et al., 2008) with a slight modiﬁcation. Brain tissues containing
mouse PRh were homogenized in ice with the electronic tissue grinder
(IKA®ULTRA-TURRAX®dispersers, Germany) in 10-fold volume of A68
buffer (10 mM Tris–HCl pH 7.4, 0.8 M NaCl, 1 Mm EGTA and 10% su-
crose) containing protease inhibitor cocktail (Roche). The homogenates
were centrifuged at 2000 g for 10min at 4 °C to removemembranes. Al-
iquot of the supernatant was used to quantify proteins. Samples were
centrifuged again at 18,000 g for 30 min at 4 °C and then supernatant
was collected into a new tube. The pellet was resuspended in 5-fold vol-
ume of A68 buffer by vortexing and was subjected to a second centrifu-
gation at 18,000 g for 30 min. The ﬁrst and second supernatants were
pooled and then incubated with 1% N-Lauryl-Sarkosyl for 1 h at RT
and subjected to ultracentrifugation at 70,000 g for 1 h at 4 °C (Optima™
MaxUltracentrifuge, BeckmanCoulter, UK). The pelletwas resuspended
in Laemmli sample buffer (Sigma-Aldrich) and denatured for 15 min at
95 °C and loaded in the gel. The remaining amountwas stored at−20 °C
until further use. (Number of mice for the study: Control: P-nase n=2,
ChABC n= 2; P301S: P-nase n= 4, ChABC n= 4).
Protein quantiﬁcation
Total protein concentration of brain homogenate was measured
using the bicinchoninic-acid (BCA) assay (Pierce, Thermo Scientiﬁc,
UK). Absorbance was read at 562 nm using a BioTek μQuant microplate
reader. Protein concentration was determined by calculation from the
standard curve using Excel software 2007 (Microsoft).
Western blot analysis of sarkosyl-insoluble tau
Proteins were separated by electrophoresis on NuPAGE® Bis–Tris
precast gel (Novex®, Life Technologies™) at 120 V for 90 min, and
then transferred to PVDF membranes (Millipore Corporation) at
30 mA for 150 min. Non-speciﬁc background of membranes was
blocked with incubation for 1 h at RT in TBS-T (10 mM Tris/HCl
pH 7.8, 100 mM NaCl, 0.05% Tween 20) plus 5% (w/v) non-fat milk,
and then washed three times with TBS-T. Membranes were incubated
with rabbit anti-human tau polyclonal antibody (1:2000, DAKO), phos-
phorylation dependent anti-tau monoclonal antibody AT8 (1:1000,
Innogenetics) or anti-β-actin antibody (1:5000, Sigma-Aldrich) over-
night at 4 °C and thenwashed three timeswith TBS-T. Thiswas followed
by incubation with donkey anti-rabbit or sheep anti-mouse IgG-
horseradish peroxidase (1:5000, GE Healthcare UK Ltd.) for 2 h at RT.
This was followed by three washes with TBS-T. All the antibody dilu-
tions were prepared in 1% non-fat milk in TBS-T and the duration of
each wash step was 10 min. The proteins were detected by enhanced
chemiluminescence (Pierce® ECL Western blotting substrate, Thermo
Scientiﬁc, UK) and recorded by chemiluminescence imaging system
(UVITEC Cambridge, UK).
Results
Progressive memory loss in Tg P301S mice
We focused our study on the PRh as it has a well-established role in
OR memory and is affected early in AD and tauopathies (Bartko et al.,
2007; Mumby and Pinel, 1994; Winters et al., 2004). Tau pathology inthe PRh of 1 and 3month-old homozygous Tg P301Smicewas character-
ized usingmonoclonal antibodyAT8which detects hyperphosphorylated
tau (Fig. 1A). A low level of immunoreactivitywith AT8was already pres-
ent at 1month, withmore intense staining at 3months. At this latter age
homozygous Tg P301S mice showed approximately 15% neuronal cell
loss in the PRh compared toWT control mice (*p b 0.05) (Fig. 1B). In ad-
dition, many neurons had abnormal dystrophic dendritic morphology in
Tg P301S mice. No difference in number of neurons was found between
1 month-old P301S mice and control mice (data not shown).
OR memory was compared between homozygous Tg P301S mice
and age-matched controls at 1, 2 and 3 months of age (Fig. 1C). Tg
P301Smice showed a progressive deﬁcit in their ORmemory compared
to controls. They had no abnormality at 1month of age but showed pro-
found memory loss at three months (one-way ANOVA, *p b 0.05). The
trend of memory deﬁcit in Tg P301S mice started at 2 months and was
signiﬁcant at 3 months (WT 0.222 ± 0.055; n = 6 vs Tg P301S
0.0569 ± 0.023; n = 10, t-test, **p = 0.0018). WT control and Tg
P301S mice explored the sample objects to a similar extent, indicating
that therewas nomajor difference inmotivation between groups at dif-
ferent ages (Fig. S1). The deﬁcit observed in 3 month-old P301S mice
was not due to a general inability to discriminate objects or assess
their familiarity/novelty, since both groups showed a similar level of
discrimination for the novel object when the delay between sample
and choice phase wasminimal at 1min (Fig. 1D). The study above com-
paredhomozygote transgenicswith controls of the same strain; in order
to conﬁrm that the loss of memory was a transgene-related effect,
P301S heterozygote (P301S Het) mice were compared to littermate
controls. The P301SHetmice, with lower transgene expression, showed
delayed tauopathy compared to the homozygotes. Three month-old
P301S Het mice did not show impaired OR memory while a signiﬁcant
deﬁcit in the OR memory was present at 7 months of age compared to
WT littermate controls (WT 0.265 ± 0.062; n = 8 vs P301S Het
0.022 ± 0.045; n= 7, t-test, **p= 0.0046). These results demonstrate
that expression of the P301S tau mutation leads to a progressive mem-
ory deﬁcit that depends on level of transgene expression.
Memory loss following focal AAV-P301S injection to the PRh
In order to conﬁrm that neurodegenerative tau pathology in the PRh
ofmice causes an ORmemory deﬁcit, human tau (4R0N) containing the
P301Smutationwas expressed in the PRh using an AAV vector as previ-
ously reported (Dassie et al., 2013). AAV-P301S was bilaterally injected
into the PRh of adult C57BL/6S mice. Control groups were generated by
injecting the same dose of AAV-fpmax (GFP control) and AAV-TauWT
(wild-type tau) into age-matched animals. In animals injected
with AAV-P301S, immunostaining for AT8 showed the presence of
hyperphosphorylated tau around the injection sites at 2 months post-
injection (Fig. 2A). The immunolabeling of AT8 was localized from ros-
tral to caudal PRh, partially affecting adjacent regions of the entorhinal
cortex and temporal association cortex (Fig. 2B). We also found PHF1
positive staining focused around the injection sites (Fig. 2C). 26% neuro-
nal cell loss was present in the PRh in the AAV-P301S injected group
compared to the control group injected with AAV-fpmax (Fig. 2D).
Mice injected with AAV-fpmax, AAV-TauWT and AAV-P301S were
assessed using the spontaneous OR task with 1 min or 3 h memory re-
tention to detect PRh-related functional impairment (Fig. 2E). Fig. 2E
shows OR memory at 2 months after injection of the vector: the AAV-
P301S injected group had a signiﬁcant deﬁcit in 3 h memory retention
compared to the other two groups (one-way ANOVA with Tukey post-
hoc test, *p b 0.05, **p b 0.01). With a short delay between sample and
choice phases showed normal discrimination, indicating that perirhinal
tauopathy did not lead to a general inability to discriminate objects or
assess their familiarity/novelty (Fig. 2E). Animals tested 1 month after
injection of the AAV-P301S vector exhibited a reduced degree of
tauopathy and OR memory deﬁcit compared to mice tested 2 months
after AAV-P301S injection (data not shown).
Fig. 1. Temporal progression of ORmemory deﬁcit in Tg P301S mice. A. Brain sections from 1 to 3 month-old P301Smice were stained with anti-hyperphosphorylated tau antibody AT8.
Tau hyperphosphorylationwas visualized byAT8 in the PRh of P301Smice. The PRh at the bregma−1.82mm is shown in a coronal brain section imagemodiﬁed frombrain atlas (Paxinos
et al., 2001). In 3month-oldmice tau immunostaining appearedmore localized in cell bodies compared to 1month-oldmice. No stainingwas present in control brain (data not shown) B.
Brains from P301Smice and age-matched control (C57BL/6S) were immunostainedwith NeuN antibody. NeuN-positive neuronswere counted by stereology quantiﬁcation. The neuronal
cell loss in the PRhwas signiﬁcant in 3month-old P301Smice compared to controls (WT n=5, P301S n=6, t-test, *p b 0.05) C. P301Smice showed the spontaneousORmemory deﬁcit in
the 3 h retention paradigm. The discrimination ratio represented as (novel− familiar object exploration time) / total exploration time. The ORmemory deﬁcit was signiﬁcant in 3month-
old P301Smice compared to control mice (WT n=6, P301S n=10, t-test, **p b 0.01). The progression of the deﬁcit was age-dependent in P301Smice. No deﬁcit was present in 1month-
old mice compared to controls (WT n= 7, P301S n= 9), while in 2 month-old mice a deﬁcit was present but it did not reach signiﬁcance (WT n=5, P301S n=7). D. Three month-old
P301S and control mice were subjected to a 1 min delay between sample and choice phases to determine whether possible visual problem in the P301Smice could have affected the re-
sults. Both P301S and control mice showed a similar strength of ORmemory after a 1min delay. E. In order to verify speciﬁcity of the transgenic effect on the deﬁcit in the spontaneous OR
task 3 and7month-old littermate control and heterozygous P301Smice (P301SHet)were tested to determine theirmemory for 3 h retention in the spontaneousOR task. Both control and
P301S Het mice showed identical ORmemory at 3 months of age (WT n=6, P301S Het n=7) but P301S Het mice showed a signiﬁcant deﬁcit compared to their littermate controls at 7
months of age (WT n= 8, P301S Het n= 7, t-test, **p b 0.01). Data are presented as mean ± SEM.
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Digestion of CSPGs in the adult CNSwith ChABC reactivates plasticity
and has a direct effect on memory. We hypothesized that treatment of
the PRhwith ChABCmight recover the profound ORmemory deﬁcit de-
scribed above. Various observations indicate that the main effect of
ChABC is through its effect on PNNs. We therefore conﬁrmed that
PNNs were present in the PRh of Tg P301S mice and therefore available
as a target for ChABC treatment (Fig. 3). PNNswere visualizedwithWFA
lectin, which binds to chondroitin sulphate chains, the target of ChABC.
The number and intensity of PNNs was similar in the P301S homozy-
gotes at 3 months compared to age-matched WT control mice (Fig. S2).
In order to attenuate the PNNs in the PRh, the CSPG-degrading en-
zyme ChABC was bilaterally injected at three different sites into
3 month-old Tg P301S mice or 7 month-old Tg P301S Het mice. The ex-
tent of PNN digestion was visualized by WFA staining two weeks after
treatment (Fig. 3A). At this time there was an obvious reduction in the
intensity of WFA staining in the injected area, indicating successful
ChABC digestion in the PRhwith some extension to the adjacent regions
including the entorhinal cortex, temporal associated cortex and caudal
hippocampus (Figs. 3A–B). We also counted WFA positive neurons in
the PRh,ﬁnding a 39% reduction twoweeks after ChABC injections com-
pared to animals injected with the control bacterial enzyme P-nase (P-
nase n=6, ChABC n=6, t-test, **p b 0.01) (Figs. 3B–C). Seven days after
ChABC or P-nase treatment animals were tested for OR memory
(Fig. 4A). The impaired OR memory found in 3 month-old P301S miceat a 3 h delay was restored to a level indistinguishable from that of con-
trol animals after ChABC treatment while animals treated with control
enzyme P-nase showed the same deﬁcit as untreated animals (P301S/
P-nase; n= 16, P301S/ChABC; n= 13, t-test, ***p= 0.0003) (Fig. 4B).
Age-matched C57BL/6S control mice showed minimal change in the
ORmemory between P-nase and ChABC treated groups at 3 h retention
(Control/P-nase; n=7, Control/ChABC; n=5, t-test, p=0.6352), as in
our previous study (Romberg et al., 2013) (Fig. 4B). Sevenmonth-old Tg
P301S Het mice which have a similar deﬁcit in ORmemory to 3 month-
old Tg P301S homozygous mice showed a similar restoration trend of
OR memory in ChABC treated animals (P301S Het/P-nase; n = 4,
P301SHet/ChABC; n=3, t-test, p=0.2155),with no effect inWT litter-
mate controls (Control/P-nase; n=4, Control/ChABC; n=4, t-test, p=
0.7567) (Fig. 4C). Although due to the variability in P301SHetmice, par-
ticularly those treated with P-nase, the results did not reach
signiﬁcance.
ChABC injection restores memory in AAV-P301S model
We next asked whether digestion of PNNs with ChABC can restore
OR memory in the focal AAV tauopathy model. Adult animals were
injected with either AAV-fpmax, AAV-TauWT or AAV-P301S at 8–9
weeks of age. At 2 months post-injection, as described above, AAV-
P301S injected mice showed a profound impairment in OR memory,
while the control AAV- fpmax or AAV-TauWT injected mice displayed
normal OR memory in the 3 h delay paradigm (Fig. 2E). Then they
Fig. 2. AAV-P301S induced neurodegenerative tauopathy and OR memory deﬁcit. A. Schematic illustration for AAV-P301S injection sites. Asterisks indicated the injection site. B. Immu-
nostainingwith AT8 antibody 2months after the bi-lateral injections of AAV-P301S into the PRh of C57BL/6Smice. Dashed lines indicate the area of the PRh. Asterisks indicate the injection
site. C. More abundant tau pathology in the PRh cortex was present compared to adjacent cortices. i) Labeling with AT8 antibody revealed the tauopathy-induced lesion on the PRh at
bregma −2.16 mm. ii) Adjacent regions such as the entorhinal cortex were not affected as much as PRh. iii) AT8-positive neurons and dendrites were present in the PRh. iv)
Hyperphosphorylated tau deposits were also detected by PHF1 antibody. Scale bar, i: 500 μm, and ii–iv: 30 μm D. Immunostaining with NeuN antibody showed a signiﬁcant neuronal
cell loss in the PRh. AAV-fpmax injected mice (i–iii) displayed less neuronal damage and signiﬁcantly more neurons compared to AAV-P301S injected mice (iv–vi). This was conﬁrmed
by stereological quantiﬁcation (AAV-fpmax n= 3, AAV-P301S n= 5, t-test, **p b 0.01). Data are presented as mean ± SEM. E. AAV-fpmax (n= 12), AAV-TauWT (n= 13) and AAV-
P301S (n = 12) injected mice were tested in the spontaneous OR task for 1 min or 3 h of memory retention. There was no difference between AAV-fpmax and AAV-P301S groups
after a 1 min delay while AAV-P301S injected mice showed a signiﬁcant impairment in OR memory following a 3 h delay. ANOVA followed by Tukey post-hoc test, *p b 0.05, **p b 0.01.
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jection paradigm as for Tg P301S mice (Fig. 3A), followed by OR testing
on the schedule described in Fig. 4A. ChABC injected AAV-P301S mice
had signiﬁcantly improved OR memory compared to P-nase injected
AAV-P301S mice in the 3 h delay paradigm (t-test, *p b 0.05) (Fig. 4D).Memory deﬁcit returns 5 weeks after ChABC treatment
Our data show that ChABC to the PRh can reverse OR memory im-
pairment in two different models of tauopathy-induced memory loss.
As shown in the schedule in Fig. 4A, the memory tests were performed
7–10 days after ChABC injection. Turnover of stable extracellular struc-
tures such as PNNs is relatively slow, so we wished to know for how
longmemory would be restored after a single ChABC injection. Staining
for PNNs in Tg P301Smice after P-nase or ChABC injection showed that
PNN intensity and number had almost returned to normal by 5 weeks
(n = 5 per group, t-test, p = 0.072) (Figs. 5A–C). We therefore mea-
sured OR memory at this time. By 5 weeks after ChABC treatment
P301S mice no longer showed the improved OR memory that was
seen at 10 days (P301S/P-nase vs P301S/ChABC, t-test, p = 0.91)
(Fig. 5D). Motivation measure by exploration time showed nodifference between groups (Control/ChABC vs P301S/ChABC, t-test,
p= 0.642) (Fig. 5E).
ChABC restores synaptic transmission
OR memory requires normal synaptic transmission in the PRh
and has been shown to involve long-term depression (LTD) in neuro-
nal responsiveness in this area (Brown et al., 1987; Grifﬁths et al.,
2008; Xiang and Brown, 1998; Zhu et al., 1996). In our previous
study on the effects of PNN depletion in the PRh ofWTmice, we dem-
onstrated an increase in synaptic transmission and LTD compared to
controls (Romberg et al., 2013). To investigate the physiological
changes in PRh when affected by tau pathology, and the effects of
ChABC, we measured PRh synaptic transmission and LTD in coronal
slices from 3 month-old Tg P301S mice with and without ChABC
treatment, and from normal age-matched controls (Fig. 6). Stimula-
tion of temporal cortex input into layer II/III of the PRh with different
stimulus intensities revealed that basal fEPSPs were signiﬁcantly di-
minished below control levels in Tg P301S mice. fEPSP amplitude
was restored to control levels following ChABC treatment showing
a signiﬁcant trend to surpass normal fEPSP values (Fig. 6A). There
was a signiﬁcant interaction between group and intensity (RM
Fig. 3.Removal of PNNs by ChABC treatment in Tg P301Smice. A. The sagittal brain atlas illustrates the injection levels of ChABC. Immunohistochemistry usingWFA in P-nase (a–c) ChABC
(a′–c′) injected Tg P301Smice at 2weeks post-injection. It showed the extent of depletion of PNNs byChABC treatment, indicated by the dotted line. B. Proﬁles ofWFA-positive PNNs in the
PRh of P301S mice at higher magniﬁcation following P-nase or ChABC injection. Scale bar, 50 μm C. Stereological analysis of WFA-positive neurons in the PRh of P301S mice following P-
nase or ChABC injection. Data are presented asmean± SEM. A signiﬁcant decrease inWFA staining is caused by ChABC injection in Tg P301Smice (P-nase n=6, ChABC n=6, t-test, **p b
0.01).
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ences between the stimulus intensity vs response curves. LTD induc-
tion was unaffected in Tg P301S animals although it was imperviousFig. 4. OR memory recovery after ChABC treatment in Tg P301S mice and AAV-P301S injected
month-oldhomozygous P301S and age-matched controlmicewere injectedwith P-nase or ChA
pared to P-nase injectedmice in spontaneous OR paradigmwith a 3 h delay (P-nase n=16, Ch
n= 7, ChABC n= 5) C. Seven month-old P301S Het and the age-matched littermate control m
applied for testing ORmemory after treatment. Similar pattern to that shown in B was observed
the results did not reach signiﬁcance. Control: P-nase n=4, ChABC n=3; P301S: P-nase n=4,
with a 3 h delay-paradigm following P-nase or ChABC treatment to the PRh cortex. The OR deﬁ
signiﬁcantly improved by ChABC treatment (t-test, *p b 0.05). AAV-fpmax: P-nase n=6, ChABCto ChABC treatment (Fig. 6B). These results show a considerable im-
pairment in synaptic transmission in Tg P301S mice. As in our previ-
ous work, the removal of PNNs greatly increased the neuronalmice. A. Experimental protocol for the OR test after P-nase or ChABC injection. B. Three
BC. ChABC injected P301Smice showed a signiﬁcant improvement in theORmemory com-
ABC n=13, t-test, ***p b 0.001) whereas control micewere not affected by ChABC (P-nase
ice were injected either with P-nase or ChABC. Spontaneous OR test with a 3 h delay was
. Although due to the variability in P301S Het mice, particularly those treatedwith P-nase,
ChABC n=4D.Mice from all AAV injected groupswere tested by the spontaneousOR task
cit exhibited in the AAV-P301S injectedmice (ANOVAwith Tukey post-hoc, *p b 0.05) was
n=6; AAV-TauWT: P-nase n=6, ChABC n=6; AAV-P301S: P-nase n=6, ChABC n=6.
Fig. 5.ORmemory deﬁcit returns 5weeks after ChABC treatment in Tg P301Smice PNNswere visualized byWFA staining in P-nase (A) or ChABC (B) injectedmice 5weeks post-injection.
The PNNs present in the PRh of P-nase (a) or ChABC (b) injectedmice were shown at higher magniﬁcation. C. Stereological quantiﬁcation ofWFA-positive cells in the PRh of P301S mice
following P-nase (n=5) or ChABC (n=5) injection. There was no signiﬁcant difference between groups (t-test, n.s: not signiﬁcant, p=0.072). D. ChABC and P-nase treated P301Smice
showed similar level of deﬁcit 5weeks following ChABC injection. At this time point, ChABC treatmentwas no longer effective in restoring theORmemory in Tg P301Smice (P-nase n=7,
ChABC n=6, t-test, n.s, p=0.91). E. The exploration time for sample phase of control and P301Smice at 5 weeks after ChABC injection, indicating that each group presented comparable
extent of motivation and that lack of motivation was not interfering with the results. Control; P-nase n= 6, ChABC n= 5, P301S; P-nase n= 7, ChABC n= 6.
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injected normal animals (Romberg et al., 2013).
Effect of ChABC injection on hyperphosphorylated tau in Tg P301S mice
The above data show that ChABC treatment reverses theORmemory
impairment in P301S mice. This functional restoration could be due to
removal of PNNs and consequent promotion of plasticity and synapse
dynamics. However, the aggregation of normal and mutant tau is inﬂu-
enced by chondroitin sulphate and heparan sulphate proteoglycans
(Goedert et al., 1996), and it is therefore possible that ChABC treatment
might inﬂuence tau aggregation in Tg P301S mice. The proﬁles of path-
ological tau in Tg P301S mice after ChABC treatment to PRh wereFig. 6. ChABC treatment altered synaptic transmission in the PRh of Tg P301S mice. A. Layer II/
intensities. WT P-nase n=11, P301S P-nase n=11, P301S ChABC n=11. Two-way RM ANOV
sented as mean± SEM. ***p b 0.001 B. LTD induced by low-frequency stimulation is not differen
PRh did not alter LTD in P301S mice. WT P-nase n= 7, P301S P-nase n= 7, P301S ChABC n=analyzed using the hyperphosphorylated tau speciﬁc antibody AT8,
and compared to mice that received P-nase treatment (Figs. 7A and
B). In the PRh, AT8 staining showed many neurons with various stages
of tau aggregation, such as “ring”-like cytoplasmic accumulation and
pre-tangle conformation. Stereological quantiﬁcation of AT8-positive
staining with all types of tau deposits showed no signiﬁcant difference
in the PRh of P301S mice 2 weeks after P-nase or ChABC injection (P-
nase n = 5, ChABC n = 3, t-test, p = 0.9697) (Fig. 7C) or at 5 weeks
after treatment (Fig. S3). In addition when cells manifesting “tangle”-
like AT8-positive staining were selectively counted in the PRh there
was no evidence that ChABC affected the pattern of tauopathy in
P301S mice (data not shown). Moreover the number of NeuN positive
neuronal cells in P301S mice was not affected by ChABC treatment atIII fEPSP amplitudes after stimulation of temporal layer II/III input with different stimulus
A: there is a statistically signiﬁcant interaction between group and intensity. Data are pre-
t between P-nase injectedWT control and P301Smice. Moreover, ChABC treatment to the
6.
Fig. 7.Tauopathy after ChABC treatment in Tg P301Smice. Hyperphosphorylated tauwas visualized byAT8 antibody immunostaining in the PRhof P-nase (A) and ChABC (B) injectedmice
at 2 weeks post-injection. AT8 (C) or NeuN-positive cells (D) were stereologically quantiﬁed in the PRh cortex of P301S mice (P-nase n= 5, ChABC n= 5). No signiﬁcant inﬂuence of
ChABC treatment on AT8 staining or neuronal cell number was present in the Tg P301S mice. E. The level of total tau protein and sarkosyl-insoluble tau in the PRh treated with either
P-nase or ChABC was analyzed by Western blotting using anti-human tau antibody. No difference was present between the two groups. Western blotting with AT8 antibody showed
the similar level of sarkosyl-insoluble hyperphosphorylated tau in the P301S mouse PRh treated with either P-nase or ChABC, indicating that the treatment did not affect insoluble tau
pathology. Control; P-nase n= 2, ChABC n= 2, P301S; P-nase n= 4, ChABC n= 4.
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(Fig. S3). We also analyzed tau levels and aggregation using a biochem-
ical assay. Fresh frozen tissue from the areas injected with P-nase or
ChABC from P301S or wild type control micewere subjected to sarkosyl
extraction (Delobel et al., 2008), in order to enrich for aggregated tau.
Western blot analyses of total protein fractions extracted from P-nase
and ChABC treated control or P301S mice did not show any difference
in the level of total tau (Fig. 7E). In the sarkosyl-insoluble fractions, con-
taining mainly the aggregated protein there was no signiﬁcant change
in the level of tau between P-nase and ChABC treated P301S mice
(Fig. 7E). This trend was observed in four independent experiments
using P301S mice. These data demonstrate that the progressive
tauopathy and neurodegeneration seen in P301Smice is not signiﬁcant-
ly affected by ChABC treatment.Discussion
The overall aim of these experiments was to ask whether promoting
plasticity and enhancing memory through modiﬁcation of PNNs could
allow the CNS to recover memory function in the presence of damage
caused by tauopathy. We ﬁrst deﬁned the time course of loss in sponta-
neous OR memory in both a transgenic mouse model of familial
tauopathy, and a focal tauopathy model induced by injection of AAV
containing a mutant tau cDNA. Selecting a time point at which there is
profound memory loss for each model, we then demonstrated that
this deﬁcit can be corrected by digestion of PNNs with ChABC, and
that electrophysiological measures of synaptic transmission can be
restored. Finally, we examined the effect of ChABC treatment on tau
pathology and found that neither the progressive tauopathy nor the
neurodegeneration seen in P301S mice was affected by a single treat-
ment with ChABC; the effect of the ChABC treatment is therefore
through promoting plasticity andmemory function rather than through
disease modiﬁcation. Previous work using ChABC to promote plasticity
has shown recovery in function in focal lesions such as spinal cord injury
and stroke (Bradbury et al., 2002; Soleman et al., 2012); the present
work shows that functional restoration can also be achieved in the pres-
ence of the more distributed neuronal dysfunction and loss created by
neurodegeneration.Tauopathy progression and memory loss
In the Tg P301S mice there is a steady progression of tau pathology
with hyperphosphorylated tau becoming more insoluble and ﬁlamen-
tous as can be seen by biochemical isolation and by electronmicroscopy
(Allen et al., 2002). At between two and threemonths of age in Tg P301S
mice many neurons start to develop dystrophic morphology, with ab-
normal dendrites and perinuclear tau accumulations. In the PRh 15%
neuronal cell loss was present at 3 months of age in homozygous
P301S mice. A similar set of events occurs after injection of AAV-
P301S into the cortex, as reported previously (Dassie et al., 2013). How-
ever, progression is faster in the injection area, and 2 months after the
AAV-P301S injection the pathology resembles that seen in the transgen-
ic animals at around 5months of age, with 26% loss of neurons in the re-
gion immediately adjacent to the injection sites. A similar time course of
memory loss was seen in the water maze test following AAV-P301S in-
jections to the entorhinal cortex in a previous paper (Dassie et al., 2013).
We testedORmemory at various ages in homozygous Tg P301S animals,
ﬁnding almost normal memory at 1 month, around 50% reduction at 2
months, and a completememory loss at 3months. Therewas an equally
profound loss of memory in the AAV-P301S animals at 2 months after
vector injection. However, animals were able to learn to recognize ob-
jects, because when placed in the Y-maze 1 min after ﬁrst exposure to
an object they were able to recognize it as familiar and discriminate it
from the novel object. On the other hand memory retention at 1 and
3 h after ﬁrst exposure to the sample objects was eliminated. At this
stage of pathology many neurons are dystrophic but few have died, so
the functional loss must be mainly due to neuronal and synaptic
dysfunction.Restoration of memory
The hypothesis that PNNdigestionmight restorememorywas based
on two previous studies. Gogolla et al. digested PNNs in the amygdala,
showing that erasure of fear conditioning memory could now be
achieved as in juveniles, changing the pattern from untreated adult an-
imals where memory is resistant to extinction (Gogolla et al., 2009).
Similarly, it has been recently reported that the enzymatic removal of
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memory without erasing the pre-existing memories (Happel et al.,
2014). Previous work from our laboratories examined OR memory in
animals with attenuated PNNs due to the Crtl1/Hapln1 gene deletion
(Crtl1 KO) in the brain resulting in a link protein knock-out (a compo-
nent of PNNs), and in normal animals, in which PNNs in the PRh were
digested with ChABC. OR memories in mice usually decay by 12 h, but
Crtl1 KO and ChABC-injected normal animals retained their memories
for over 48 h (Romberg et al., 2013). Whereas that study used normal
mice, the present study shows that even inmicewith brains extensively
damaged by neurodegeneration, digestion of PNNs can restore OR
memory. This effect is possibly due to “activation” of neurons without
tau pathology since we have observed that PNNs are mainly present
around parvalbumin-positive interneurons without neuroﬁbrillary tan-
gles (SY unpublished observations). The memory enhancing effect in
the mice with tauopathy was completely diminished by 5 weeks after
ChABC treatment. However this effect might be prolonged if CSPG di-
gestion is achieved for longer time for example by using ChABC gene de-
livery via lentiviral vector (Bartus et al., 2014).
PNNs and memory
Although our study is focused on the effect of ChABC on PNNs they
only contain 2% of brain CSPGs (Deepa et al., 2006). Therefore other tar-
gets of the enzyme cannot be excluded. However, the identiﬁcation of
PNNs as the target of ChABC digestion comes from the ﬁnding that ani-
mals lacking PNNs due to deletion of a link protein in the CNShave iden-
tical changes in plasticity to those treated with ChABC, and that further
treatment of Crtl1 KO animals with ChABC (removing the remaining
98% of glycans) has no additional effect onmemory (Carulli et al., 2010).
Themechanism bywhich PNNsmight affectmemory is not fully un-
derstood. PNNs are found particularly around parvalbumin-positive
GABAergic interneurons. These cells control the initiation and termina-
tion of the developmental critical periods, termination being dependent
on the formation of PNNs (Beurdeley et al., 2012; Pizzorusso et al.,
2002). Parvalbumin-positive interneurons are responsible for control-
ling overall levels of inhibition, generation of rhythms and network syn-
chronization (Bartos et al., 2007; Le Magueresse and Monyer, 2013).
Interference with the function of these cells by transgenicmanipulation
of glutamate receptors or expression of tetanus toxin leads to impaired
memory, and affects gamma oscillations which provide a temporal
structure for information processing, including memory formation
(Korotkova et al., 2010;Murray et al., 2011). Duringmemory acquisition
or after ChABC treatment the level of inhibitory synaptic input to
parvalbumin-positive interneurons increases; this is accompanied by a
decrease in the level of parvalbumin and the level of the enzyme gluta-
mate acid dehydroxylase (responsible for GABA production) suggesting
a lower level of cortical inhibition (Donato et al., 2013). Furthermore,
PNNs have several properties that could affect synaptic function.
Brevican, a PNN component, binds AMPA receptors, restricting their
mobility and affecting short-term plasticity (Frischknecht et al., 2009),
with the neuronal activity-related pentraxin (NARP) as a probable
scaffolding intermediate (Gu et al., 2013). PNNs bind to and present a
variety of molecules, including Semaphorin 3A, which has marked
effects on synapse dynamics. Interference with Sema3A/Neuropilin-1/
PlexinA4 signaling during development results in lasting changes in
cortical neuron basal dendrite patterning, arborization and spine
formation (Fenstermaker et al., 2004; Tran et al., 2009; Yamashita
et al., 2007), Sema3A affects synaptic transmission in hippocampal neu-
rons (Bouzioukh et al., 2006; Sahay et al., 2005) and blocking Sema3A
receptors partially restores ocular dominance plasticity to the cortex
(Pizzorusso unpublished observations). CSPGs are a major component
of the PNNs and they have inhibitory effects via the PTPσ receptor,
which is widely expressed in the cortex (Shen et al., 2009). It is possible
that the dense and stable matrix in which synapses are embedded af-
fects their behavior and the possibility of forming new connections.The PNNalso bindsOtx2,whichmaintains thematurity of the structures
(Beurdeley et al., 2012; Spatazza et al., 2013). In addition, digestion
of CSPGs can promote sprouting of new connections and restoration
of function despite large CNS lesions (Kwok et al., 2011). Some degree
of rewiring of the cortex as seen after CNS lesions must be necessary
to compensate for neuronal loss in neurodegenerative disease. Indeed,
we saw evidence for effects on synaptic transmission in our study,
which might be a consequence of compensational rewiring of neuronal
activity. Cortical slices from Tg P301S mice showed a marked diminu-
tion of fEPSP size in response to temporal stimulation, but this measure
of synaptic activity was restored to normal or above following ChABC
treatment, suggesting that some of the mechanisms mentioned above
affect synapse number and/or activity.
Treatment of neurodegenerative disease
At present there are no treatments that modify disease progression
sufﬁciently to haltmemory decline inAlzheimer's disease or tauopathies
in human patients. Symptomatic treatment with memory-enhancing
compounds such as cholinesterase inhibitors is modestly effective at
some stages of the disease. The effect of ChABC that we have demon-
strated suggests that manipulation of PNNs might be an alternative
way of restoring memory, at least temporarily, in neurodegenerative
disease. In the twomousemodels that we have presented, ChABC treat-
ment restored memory in the presence of advanced pathology. The ef-
fect of ChABC on diffuse pathology is not restricted to tau pathology,
because in a recent experiment ChABC was injected into the hippocam-
pus of transgenic mice with an amyloidopathy model of neurodegener-
ative disease (APP/PSI mice), demonstrating restoration of fear memory
and in increase in LTP (Vegh et al., 2014). However, ChABC itself is not a
viable treatment for neurodegenerative diseases; it has to be injected di-
rectly into the CNS because it does not cross the brain–blood barrier, and
as we show its effects last for less than ﬁve weeks, the time taken by de-
graded PNNs to be normalized again. However other compounds, cur-
rently under development, that affect the PNNs in other ways, through
actions on the glycan chains of CSPGs or targeting other PNN compo-
nents could be effective in improving memory in these devastating dis-
eases with tau pathology. The open question is how long it would be
possible to postpone the loss of CNS function for example in Alzheimer's
disease by using a PNN-targeted treatment. The ﬁnding that we were
able to restore normal memory in the presence of advanced tau pathol-
ogy suggests that a signiﬁcant delaymight be achieved inmemory decay
in tauopathies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.expneurol.2014.11.013.
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